OverviewSuggest Edit
AstraZeneca is a global science-led biopharmaceutical company specializing in the discovery, development, manufacturing, and marketing of prescription medicines. It develops drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology. The company offers its products to primary care and specialty care physicians through distributors and local representative offices.
| Type | Public | |
| Founded | 1999 | |
| HQ | Cambridge, GB | Map |
| Website | astrazeneca.com | |
| Employee Ratings | More | |
| Overall Culture | B | More |
Recent NewsAll News
- Insights on the Hairy Cell Leukemia Drugs Global Market to 2025 - Players Include Amgen, Astex Therapeutics and AstraZeneca Among Others
- Philippines to Get 20 Million Additional Doses From AstraZeneca
- HRH The Prince of Wales unveils new sustainability charter, backed by the likes of Bank of America and AstraZeneca
- Thinking about trading options or stock in Moderna, Plug Power, Aurora Cannabis, AstraZeneca, or Bank of America?
Key People/Management at AstraZeneca
Pascal Soriot
Marc Dunoyer
Katarina Ageborg
Pam Cheng
Ruud Dobber
David Fredrickson
AstraZeneca Office Locations
AstraZeneca Financials and Metrics
AstraZeneca Revenue
| USD | |
|---|---|
Revenue (Q3, 2020) | 6.6b |
Gross profit (Q3, 2020) | 5.2b |
Gross profit margin (Q3, 2020), % | 79.2% |
Net income (Q3, 2020) | 651.0m |
EBIT (Q3, 2020) | 1.2b |
Market capitalization (15-Jan-2021) | 99.7b |
Closing stock price (15-Jan-2021) | 75.9 |
Cash (30-Sept-2020) | 8.1b |
EV | 113.9b |
| USD | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 5.4b | 5.1b | 6.2b | 5.2b | 5.2b | 5.3b | 5.5b | 5.8b | 6.4b | 6.4b | 6.3b | 6.6b |
Cost of goods sold | 894.0m | 950.0m | 1.2b | 1.1b | 1.0b | 1.2b | 1.1b | 1.1b | 1.4b | 1.4b | 984.0m | 1.4b |
Gross profit | 4.5b | 4.1b | 5.0b | 4.0b | 4.1b | 4.2b | 4.4b | 4.8b | 5.1b | 4.9b | 5.3b | 5.2b |
Gross profit Margin, % | 83% | 81% | 80% | 78% | 80% | 78% | 79% | 82% | 79% | 78% | 84% | 79% |
| USD | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 3.1b | 5.2b | 4.0b | 3.0b | 3.0b | 3.4b | 4.1b | 5.4b | 4.0b | 3.4b | 5.7b | 8.1b |
Inventories | 2.7b | 2.9b | 3.2b | 3.3b | 3.1b | 3.0b | 3.1b | 3.2b | 3.1b | 3.1b | 3.6b | 3.7b |
Current Assets | 11.6b | 14.3b | 13.6b | 13.2b | 12.4b | 13.1b | 13.6b | 15.2b | 13.5b | 12.8b | 14.9b | 18.2b |
PP&E | 7.0b | 7.1b | 7.3b | 7.7b | 7.5b | 7.6b | 7.4b | 7.4b | 7.3b | 7.3b | 7.5b | 7.7b |
| USD | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Depreciation and Amortization | 658.0m | 1.3b | 1.9b | 709.0m | 1.4b | 2.1b | 676.0m | 1.4b | 2.1b | 841.0m | 1.6b | 2.4b |
Cash From Operating Activities | 88.0m | 338.0m | 2.6b | (140.0m) | (75.0m) | 394.0m | (387.0m) | 491.0m | 1.6b | 139.0m | 1.2b | 3.0b |
Purchases of PP&E | (286.0m) | (549.0m) | (849.0m) | (213.0m) | (486.0m) | (728.0m) | (174.0m) | (438.0m) | (659.0m) | (186.0m) | (370.0m) | (598.0m) |
Cash From Investing Activities | (146.0m) | (351.0m) | (686.0m) | 273.0m | 177.0m | 36.0m | 328.0m | (789.0m) | (715.0m) | 9.0m | 157.0m | (423.0m) |
| USD | Q1, 2017 |
|---|---|
Debt/Equity | 1.2 x |
Debt/Assets | 0.3 x |
Financial Leverage | 4.1 x |
P/E Ratio | 71.0 |
AstraZeneca Acquisitions / Subsidiaries
| Company Name | Date | Deal Size |
|---|---|---|
| Alexion Pharmaceuticals | December 12, 2020 | $39 b |
| Takeda Respiratory Business | May 10, 2016 | $575 m |
| AcertaPharma | December 17, 2015 | $4 b |
| ZS Pharma | November 06, 2015 | $2.70 b |
| Almirall | July 30, 2014 | |
| Pearl Therapeutics | June 10, 2013 | $1.20 b |
| Omthera Pharmaceuticals | May 29, 2013 | $323 m |
| Ardea Biosciences | April 23, 2012 | $781 m |
| Guangdong BeiKang Pharmaceutical Company Ltd | December 08, 2011 | |
| Novexel | December 23, 2009 |
AstraZeneca Revenue Breakdown
AstraZeneca revenue breakdown by business segment: 10.7% from Other Disease Areas, 22.1% from Respiratory, Inflammation and Autoimmunity, 35.5% from Oncology, 28.3% from Cardiovascular and Metabolic Diseases and 3.4% from Other
AstraZeneca revenue breakdown by geographic segment: 17.1% from Continental Europe, 38.3% from Americas, 37.2% from Asia, Africa & Australasia and 7.5% from UK
AstraZeneca Cybersecurity Score
AstraZeneca Environment, Social & Governance (ESG) Ratings
AstraZeneca Online and Social Media Presence
228.61k Twitter followers
AstraZeneca has 228.61k Twitter Followers. The number of followers has increased 4.6% month over month and increased 9% quarter over quarter
AstraZeneca's Trends
Twitter Engagement Stats for @astrazeneca
7.4k
Tweets
1.7k
Following
228.6k
Followers
21
Tweets last 30 days
126.7
Avg. likes per Tweet
100%
Tweets with engagement
AstraZeneca Company Culture
Overall Culture
B
70/100
CEO Rating
B
70/100
Compensation
A+
81/100
AstraZeneca News and Updates
Insights on the Hairy Cell Leukemia Drugs Global Market to 2025 - Players Include Amgen, Astex Therapeutics and AstraZeneca Among Others
Philippines to Get 20 Million Additional Doses From AstraZeneca
HRH The Prince of Wales unveils new sustainability charter, backed by the likes of Bank of America and AstraZeneca
Thinking about trading options or stock in Moderna, Plug Power, Aurora Cannabis, AstraZeneca, or Bank of America?
COVID-19 Live Updates: UK Man Becomes First Patient In The World To Receive AstraZeneca Vaccine
Thinking about buying stock in AzurRx BioPharma, AstraZeneca, Marathon Patent Group, Mogo Inc, or Phunware?
AstraZeneca Blogs
AstraZeneca Frequently Asked Questions
When was AstraZeneca founded?
AstraZeneca was founded in 1999.
Who are AstraZeneca key executives?
AstraZeneca's key executives are Pascal Soriot, Marc Dunoyer and Katarina Ageborg.
How many employees does AstraZeneca have?
AstraZeneca has 70,600 employees.
What is AstraZeneca revenue?
Latest AstraZeneca annual revenue is $24.4 b.
What is AstraZeneca revenue per employee?
Latest AstraZeneca revenue per employee is $345.4 k.
Who are AstraZeneca competitors?
Competitors of AstraZeneca include Daiichi Sankyo, Boehringer Ingelheim and Sanofi.
Where is AstraZeneca headquarters?
AstraZeneca headquarters is located at 1 Francis Crick Ave, Cambridge.
Where are AstraZeneca offices?
AstraZeneca has offices in Cambridge, Harlow, London, Luton and in 107 other locations.
How many offices does AstraZeneca have?
AstraZeneca has 119 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies